- BeiGene began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong and Shanghai.
- Jinan Qilu Pharma entered a $300 million agreement to acquire greater China rights to an RNAi therapy for hepatitis B developed by Arbutus Bio.
- Jiangsu Hansoh Pharma acquired China rights to a novel cytopenia therapy from Keros Therapeutics in a $190 million agreement.
- Shanghai Everest Medicines partnered with Providence Therapeutics, an Alberta company, to develop a new COVID-19 vaccine that targets the Omicron variant.
For further details see:
Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board